Optometrists in Springfield, MI Accepting Medicare
4 Optometrists found. Showing 1 - 4
 William Francis Waterbury Ii, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 228 N. Helmer Rd., Springfield, MI 49037 Phone: 269-963-5640 Fax: 269-963-1666 |
 Todd G Stagner Od Pllc Optometrist - Corneal and Contact Management Medicare: Medicare Enrolled Practice Location: 228 N Helmer Rd, Springfield, MI 49037 Phone: 269-963-5640 |
Todd G Stagner, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 228 N Helmer Rd, Springfield, MI 49037 Phone: 269-963-5640 Fax: 269-963-1666 |
Mr. David W Lucas, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 228 N Helmer Rd, Springfield, MI 49037 Phone: 269-963-5640 Fax: 269-963-1666 |
News Archive
VYTORIN reduces major vascular events in patients with chronic kidney disease
In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)
LincRNAs play key roles during embryonic brain development
Whitehead Institute scientists have identified conserved, long intervening non-coding RNAs (lincRNAs) that play key roles during embryonic brain development in zebrafish. They also show that the human versions of the lincRNAs can substitute for the zebrafish versions, which implies that the functions of these non-coding RNAs have been retained in humans as well as fish.
VG Life Sciences' peptide awarded US patent for HIV treatment
The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection.
Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA
Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.
› Verified 5 days ago
Optometrists
Chiropractors
Physical Therapists
Occupational Therapists
Speech-Language Pathologists